预约演示

更新于：2026-04-03

Pembrolizumab

帕博利珠单抗

更新于：2026-04-03

概要

基本信息

药物类型

单克隆抗体

别名

Lambrolizumab、Pembrolizumab (Genetical Recombination)、Pembrolizumab (genetical recombination) (JAN)

+ [11]

靶点

PD-1

作用方式

抑制剂

作用机制

PD-1抑制剂(细胞程序性死亡-1抑制剂)

治疗领域

肿瘤免疫系统疾病感染+ [12]

在研适应症

错配修复缺陷或微高卫星不稳定性结肠癌肿瘤卵巢癌+ [330]

非在研适应症

肢端雀斑恶性黑色素瘤NPM1突变急性髓系白血病转移性腺癌+ [108]

原研机构

Merck & Co., Inc.

在研机构

Merck Sharp & Dohme Corp.

默沙东研发（中国）有限公司Merck Sharp & Dohme LLC

+ [15]

非在研机构

Turnstone Biologics Corp.

Viralytics Pty Ltd.

权益机构

Nektar Therapeutics

NeoImmuneTech, Inc.

Canada Pension Plan Investment Board

+ [80]

最高研发阶段批准上市

首次获批日期

美国 (2014-09-04),

黑色素瘤

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、突破性疗法 (美国)、加速批准 (美国)、孤儿药 (美国)、优先审评 (中国)、突破性疗法 (中国)、附条件批准 (中国)、孤儿药 (日本)、优先审评 (澳大利亚)、孤儿药 (澳大利亚)、优先药物（PRIME） (欧盟)

登录后查看时间轴

结构/序列

Sequence Code 93660H

来源: *****

Sequence Code 93670L

来源: *****

关联

2,596

项与帕博利珠单抗相关的临床试验

NCT05077215

/ Not yet recruiting临床3期

A Phase 3, Randomized, Open-Label, Active-Controlled, Superiority Trial of EG007, Added to the Combination of Lenvatinib Plus Pembrolizumab vs. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV). This trial will be preceded by a safety lead-in study with up to 28 patients (the safety lead-in is a separate, free-standing protocol).
Approximately 450 patients will be randomized equally (1:1) to receive EG-007 plus Len+Pem or Len+Pem alone. The randomization will be stratified by the following stratification factors:
* Diagnosis Classification (advanced Stage III/IV vs. recurrent endometrial cancer)
* ECOG score at baseline (0 vs 1)
* Geographic region (Asia vs ROW)

开始日期2026-12-01

申办/合作机构

Evergreen Therapeutics, Inc

NCT07460206

/ Not yet recruiting临床2期IIT

Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment - PRELUDE Study

This study is being performed as a single-arm open-label study in order to provide information on the potential benefits of the combination of pembrolizumab and lenvatinib in participants with advanced ccRCC who have progressed on Pembrolizumab as their prior therapy in the adjuvant RCC setting.

开始日期2026-08-01

申办/合作机构-

NCT05106127

/ Not yet recruiting临床2期

A Phase 2, Open-Label, Safety Lead-In With Long Term Safety Study of EG-007, Added to the Combination of Lenvatinib Plus Pembrolizumab

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients.
A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.

开始日期2026-08-01

申办/合作机构

Evergreen Therapeutics, Inc

100 项与帕博利珠单抗相关的临床结果

登录后查看更多信息

100 项与帕博利珠单抗相关的转化医学

登录后查看更多信息

100 项与帕博利珠单抗相关的专利（医药）

登录后查看更多信息

9,577

项与帕博利珠单抗相关的文献（医药）

2026-12-31·Human Vaccines & Immunotherapeutics

Mapping research trends in esophageal cancer immunotherapy: A decade of thematic evolution and emerging priorities

Review

作者: Zang, Qiwei ; Jia, Huijun ; Wei, Hongyu ; Gong, Yifan ; Zhao, Chengguang

Immunotherapy has become a pivotal therapy for various cancers, including esophageal cancer, showing promising potential in improving survival rates and enabling personalized care. However, significant challenges occur in identifying predictive biomarkers, refining combination therapies, and managing immunotherapy-related adverse effects. This bibliometric study analyzed publications related to the use of immunotherapy in esophageal cancer management over a 10-y period (January 1, 2015, to October 14, 2024), retrieved from the Web of Science Core Collection. Keyword co-occurrence and co-citation analyses were performed to identify key contributors, central themes, and influential publications. A total of 545 publications on esophageal cancer immunotherapy were included in the analysis. A sharp increase in publication volume was observed beginning in 2019, with a peak between 2021 and 2023. China emerged as the leading contributor, accounting for 67.7% of the total output, while Zhengzhou University produced the highest number of publications among all institutions. Prominent individual contributors included Ken Kato and Shen Lin. Research hotspots centered on PD-1/PD-L1 inhibitors, combination therapies, and tumor microenvironment modulation. Notably, a clear temporal evolution in research focus was observed, with early studies emphasizing specific immune checkpoint targets and agents (e.g., PD-1, Pembrolizumab, and CTLA-4), followed by a shift toward mechanistic investigations involving the tumor microenvironment, treatment resistance, and prognosis. This study provides a comprehensive view of immunotherapy in the management of esophageal cancer, offering direction for future research and valuable insights for clinical innovation.

2026-12-31·JOURNAL OF MEDICAL ECONOMICS

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States

Article

作者: Chafamo, Biruk ; Fernan, Catherine ; Muston, Dominic ; Johnson, Geoffrey ; Qian, Feng ; Tang, Yuexin ; Bensimon, Arielle G. ; Adkins, Douglas ; Zheng, Dandan ; Tzontcheva, Anjela ; Benjamin, Kimberly ; Uppaluri, Ravindra

AIMS:

In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then continued with standard-of-care [SOC] radiotherapy +/- cisplatin after surgery followed by pembrolizumab alone) significantly prolonged event-free survival vs. SOC alone, both in the intention-to-treat population and PD-L1 combined positive score (CPS) ≥1 subgroup. Perioperative pembrolizumab + SOC received Food and Drug Administration approval in June 2025 for resectable LA HNSCC expressing PD-L1 (CPS ≥ 1). The present study evaluated the cost-effectiveness of perioperative pembrolizumab + SOC versus SOC in this indication, from a US healthcare payer perspective.

MATERIALS AND METHODS:

A Markov cohort model with four states (event-free, local recurrence, incurable recurrence/progression, death) was developed to estimate lifetime costs, life years (LYs), and quality-adjusted LYs (QALYs) with 3% annual discounting. Transition probabilities were fitted to patient-level time-to-event data from KEYNOTE-689 through parametric multistate modelling. Costs of initial and subsequent treatment, adverse events, disease management, and terminal care were estimated in 2025$ based on trial results, drug labels, public databases, and literature. Utilities were derived through analyses of EQ-5D-5L data collected in KEYNOTE-689. Deterministic and probabilistic sensitivity analyses were performed.

RESULTS:

Compared to SOC, perioperative pembrolizumab + SOC increased total costs by $82,311 and provided gains of 1.47 QALYs and 1.77 LYs. Incremental cost-effectiveness ratios of perioperative pembrolizumab + SOC vs. SOC were $55,863/QALY and $46,406/LY. Higher initial treatment costs of perioperative pembrolizumab (incurred mainly in Year 1) were partially offset by lower recurrence-related costs. At the typical $150,000/QALY threshold, perioperative pembrolizumab + SOC was cost-effective in 96% of probabilistic simulations.

LIMITATIONS:

Survival extrapolations beyond the available trial period are subject to uncertainty.

CONCLUSIONS:

Perioperative pembrolizumab + SOC was found to be cost-effective versus SOC for the treatment of resectable LA HNSCC with CPS ≥ 1.

2026-12-31·OncoImmunology

A mixed inflammatory peripheral signature defines clinical outcomes in a phase II trial combining pembrolizumab with paclitaxel and carboplatin in melanoma

Article

作者: Cocolakis, Eftihia ; Cailhier, Jean-François ; Lapointe, Réjean ; Thébault, Paméla ; Lepage, Stéphanie ; Shechtman, Yelena ; Letendre, Caroline ; Le, Huy ; Dionne, Jeanne ; Jamal, Rahima ; Bélanger, Karl ; Lambert, Caroline ; Miller Jr, Wilson H.

Checkpoint blockade of PD-1 with pembrolizumab provides long-term survival to a significant proportion of patients with metastatic melanoma. Pembrolizumab has been successfully used in combination with chemotherapy in non-small-cell lung cancer to increase the response rate. This phase II trial combined pembrolizumab with carboplatin/paclitaxel (CP) to assess its safety and efficacy, and to identify correlates of responses. Thirty patients without prior immunotherapy for unresectable/metastatic melanoma were treated with pembrolizumab and CP. Peripheral blood was collected at baseline and after 2 cycles to characterize systemic immune activity by multiplex assays and flow cytometry. Seventy percent of patients received all 4 cycles of CP; 87% received pembrolizumab for 2 y or until progression. Grade 3 and higher adverse events (AEs) occurred in 50% of the patients. The overall response rate (ORR) and disease control rate (DCR) by irRC criteria were 43% and 53%, respectively. Median overall survival (OS) was 23.8 months. Objective response was associated with a lower frequency of naive CD8 T cells and low plasma CCL3 at baseline, along with a larger proportion of mature NK cells and of CD4 T cells expressing BTLA or LAIR-1. Survival rate was higher for patients with lower baseline of IL-6, IL-8, and CD4⁺CD39⁺ T cells. Following treatment, pro-inflammatory soluble factors increased in both responders and non-responders. Addition of CP to pembrolizumab in this study did not appear to result in a response or survival advantage and was less tolerable than immunotherapy alone. Correlative data point to peripheral signals to investigate further as potential biomarkers. Trial registration: clinicaltrials.gov, NCT02617849, registered on December 1st, 2015.

12,373

项与帕博利珠单抗相关的新闻（医药）

2026-04-02

·FiercePharma

Another AstraZeneca Emerald glimmers as Imfinzi, Imjudo delay liver cancer progression

The Emerald-3 showing draws a resemblance to AstraZeneca’s Emerald-1 readout in the same locoregional treatment setting among liver cancer patients eligible for TACE. Another green light appears increasingly within reach for AstraZeneca’s Emerald program after a combo regimen featuring the company’s immunotherapy duo, Imfinzi and Imjudo, showed benefit in certain liver cancer patients. Results from the phase 3 Emerald-3 trial showed that the combination, paired with transarterial chemoembolizaton (TACE) and Lenvima, significantly improved progression-free survival (PFS) versus TACE alone in patients with unresectable locoregional hepatocellular carcinoma. Lenvima is a multikinase inhibitor sold by Merck & Co. and Eisai.But whether AZ has struck gold with Emerald-3 remains to be seen. Overall survival (OS), a secondary endpoint that will be a key consideration for the FDA, was immature at the interim analysis, although AZ highlighted a trend toward improvement in its April 2 announcement. In two ways, the Emerald-3 showing draws a resemblance to AZ’s Emerald-1 readout in the same locoregional treatment setting among liver cancer patients eligible for TACE. Two years ago, the Emerald-1 trial hit its primary endpoint, showing that a cocktail of Imfinzi, Avastin and TACE reduced the risk of progression or death by 23% versus TACE alone. At that time, OS was also immature, and AZ’s oncology R&D chief, Susan Galbraith, Ph.D., flagged that patient survival data are crucial in this locoregional setting. Case in point: Despite a PFS win, Merck & Co. last year abandoned hopes for a similar liver cancer approval for its Keytruda-Lenvima-TACE regimen after it failed to improve OS compared with TACE alone.Emerald-1 still hasn’t reported its final OS data, and the study has not graduated to the regulatory submission batch in AZ’s most recent earnings report in February. In addition, like Emerald-1, Emerald-3 has a second experimental arm. In this cohort, Imfinzi, Imjudo and TACE—without Lenvima—showed what AZ called “strong trends” toward improved PFS and OS, although these analyses were not formally tested. Previously, in Emerald-1, only the Avastin-containing triplet beat TACE, while Imfinzi-TACE failed to move the needle. AZ is discussing the latest Emerald-3 data with global regulatory authorities while waiting for final results from the trial’s key secondary endpoints, Galbraith said in an April 2 statement.As for Emerald-1, an AZ spokesperson said the company will share additional data in the future and will update its regulatory discussion plans as appropriate. Liver cancer helped AZ’s CTLA-4 agent Imjudo break into the market in 2022 as part of a combination with Imfinzi in unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. Patients who are eligible for embolization have an earlier stage of disease. In 2026, more than 200,000 patients belong to this category, according to data cited by AZ—however, most patients who receive the procedure experience progression or recurrence within six to ten months.The British pharma also has a third Emerald. Called Emerald-2, the phase 3 study is testing Imfinzi with Avastin in adjuvant liver cancer, with its data expected in the second half of 2026. As for the Imfinzi-Imjudo duo, AZ also expects readouts this year from its Nile trial in first-line metastatic bladder cancer and from its Volga study assessing a neoadjuvant regimen in cisplatin-ineligible muscle-invasive bladder cancer. Both will need to live up to the high expectations set by the combination of Merck & Co.’s Keytruda and Pfizer and Astellas’ antibody-drug conjugate Padcev.For AZ’s broader oncology portfolio, the company is bracing for an upcoming FDA advisory committee meeting that will dig into two separate applications for its oral SERD med camizestrant and the AKT inhibitor Truqap. The high-stakes first-line non-small cell lung cancer readout for Daiichi Sankyo-partnered Datroway from the Avanzar trial is also expected this year.

临床3期临床结果抗体药物偶联物临床2期

2026-04-02

·同写意

天演药业公布Muzastotug联合帕博利珠单抗最新研究数据

2026-04-02

·同写意

天演药业宣布与Incyte达成临床合作

100 项与帕博利珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10574	帕博利珠单抗	L01XC18	DB09037

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
错配修复缺陷或微高卫星不稳定性结肠癌	美国	Merck Sharp & Dohme LLC	2026-02-10
肿瘤	美国	Merck Sharp & Dohme LLC	2026-02-10
卵巢癌	美国	Merck Sharp & Dohme LLC	2026-02-10
肌层浸润性膀胱癌	美国	Merck Sharp & Dohme LLC	2025-11-21
局部晚期头颈部鳞状细胞癌	欧盟	Merck Sharp & Dohme BV	2025-10-30
局部晚期头颈部鳞状细胞癌	冰岛	Merck Sharp & Dohme BV	2025-10-30
局部晚期头颈部鳞状细胞癌	列支敦士登	Merck Sharp & Dohme BV	2025-10-30
局部晚期头颈部鳞状细胞癌	挪威	Merck Sharp & Dohme BV	2025-10-30
不可切除的肝细胞癌	中国	Merck Sharp & Dohme LLC	2025-06-10
不可切除的胸膜恶性间皮瘤	欧盟	Merck Sharp & Dohme BV	2025-04-16
不可切除的胸膜恶性间皮瘤	冰岛	Merck Sharp & Dohme BV	2025-04-16
不可切除的胸膜恶性间皮瘤	列支敦士登	Merck Sharp & Dohme BV	2025-04-16
不可切除的胸膜恶性间皮瘤	挪威	Merck Sharp & Dohme BV	2025-04-16
不可切除的尿路上皮癌	欧盟	Merck Sharp & Dohme BV	2024-07-25
不可切除的尿路上皮癌	冰岛	Merck Sharp & Dohme BV	2024-07-25
不可切除的尿路上皮癌	列支敦士登	Merck Sharp & Dohme BV	2024-07-25
不可切除的尿路上皮癌	挪威	Merck Sharp & Dohme BV	2024-07-25
晚期子宫内膜癌	美国	Merck Sharp & Dohme LLC	2024-06-17
MSI-H 子宫内膜癌	美国	Merck Sharp & Dohme LLC	2024-06-17
错配修复缺陷子宫内膜癌	美国	Merck Sharp & Dohme LLC	2024-06-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性铂耐药性卵巢癌	申请上市	美国	Merck & Co., Inc.	2025-10-20
小肠癌	申请上市	欧盟	Merck Sharp & Dohme Corp.	2022-03-25
铂耐药上皮性卵巢癌	临床3期	美国	Mural Oncology, Inc.	2022-01-10
铂耐药上皮性卵巢癌	临床3期	澳大利亚	Mural Oncology, Inc.	2022-01-10
铂耐药上皮性卵巢癌	临床3期	奥地利	Mural Oncology, Inc.	2022-01-10
铂耐药上皮性卵巢癌	临床3期	比利时	Mural Oncology, Inc.	2022-01-10
铂耐药上皮性卵巢癌	临床3期	加拿大	Mural Oncology, Inc.	2022-01-10
铂耐药上皮性卵巢癌	临床3期	捷克	Mural Oncology, Inc.	2022-01-10
铂耐药上皮性卵巢癌	临床3期	法国	Mural Oncology, Inc.	2022-01-10
铂耐药上皮性卵巢癌	临床3期	德国	Mural Oncology, Inc.	2022-01-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02617849 (Pubmed \| Oncoimmunology)	临床2期	黑色素瘤	30	Pembrolizumab and Carboplatin/ Paclitaxel	選網齋鑰齋鹽鏇觸選憲(獵衊願蓋繭繭願窪繭獵) = 蓋齋壓築膚壓糧網蓋鏇選衊鹽蓋鬱窪夢積鑰繭 (鬱觸夢鬱遞夢壓鏇鹹壓 ) 更多	不佳	2026-12-31
NCT03457948 (AACR2026)	临床2期	胃肠胰神经内分泌肿瘤	26	177Lu-DOTATATE plus pembrolizumab	窪淵襯衊鏇淵壓觸鑰壓(醖餘壓構餘淵膚壓鹽鹽) = significantly elevated (p<0.05) and exhibited prominent clonal expansion in epNET responders, particularly post treatment 願襯遞顧構範遞醖艱顧 (選遞蓋壓廠鑰獵構構鏇 ) 更多	积极	2026-04-21
AACR2026	临床2/3期	晚期头颈部鳞状细胞癌一线	398	PembrolizumabDurvalumabNivolumabumaIpilimumabTremelimumab + PembrolizumabDurvalumabNivolumab + IpilimumabTremelimumab + PembrolizumabDurvalumabNivolumabbIpilimumabTremelimumab + PembrolizumabDurvalumabNivolumabb +IpilimumabTremelimumab	襯壓遞範艱繭餘築艱繭(襯餘壓窪膚齋衊顧夢簾): HR = 1.73 (95.0% CI, 1.49 ~ 2.01) 更多	不佳	2026-04-21
				Chemotherapy
AACR2026	N/A	转移性非小细胞肺癌一线	11,758	Atezolizumab	夢鏇鏇襯夢夢襯憲憲窪(網簾鬱網餘餘醖糧繭遞) = 膚範簾繭襯衊窪鬱衊齋膚鏇積艱鹹獵簾獵淵鹽 (遞鏇觸願鹹鏇獵鏇襯構 ) 更多	不佳	2026-04-21
				Pembrolizumab	夢鏇鏇襯夢夢襯憲憲窪(網簾鬱網餘餘醖糧繭遞) = 鑰鑰願蓋窪網壓鏇壓鹽膚鏇積艱鹹獵簾獵淵鹽 (遞鏇觸願鹹鏇獵鏇襯構 ) 更多
AACR2026	临床2/3期	膀胱癌一线	200	ICI-only regimen(Durvalumab, Durvalumab+Tremelimumab, Pembrolizumab)	淵餘廠鹽鹽夢膚膚願選(夢鹹觸憲蓋蓋繭壓繭憲): HR = 1.92 (95.0% CI, 1.63 ~ 2.25) 更多	不佳	2026-04-21
				chemotherapy
NCT03983668 (CTgov)	临床1/2期	难治性霍奇金淋巴瘤 \| 非霍奇金淋巴瘤 \| 淋巴瘤	14	CMP-001+Pembrolizumab	鬱鹹膚窪齋憲鏇蓋繭襯 = 鑰網獵遞壓憲積願鑰顧糧製願願鏇衊襯積築餘 (壓網蓋構積壓範淵醖顧, 顧鏇範顧膚鏇餘膚積餘 ~ 壓廠壓構衊膚願鑰衊壓) 更多	-	2026-03-30
NCT03197506 (CTgov)	临床2期	多形性胶质母细胞瘤	52	temozolomide+pembrolizumab (Group 1 Dose Level 1 Cohort 1)	衊鑰鬱淵膚鹹網衊餘繭 = 繭壓鑰糧鑰選顧夢醖淵壓製餘膚衊醖醖範繭觸 (顧鹽鑰餘壓鬱觸淵鹹窪, 鏇鬱夢鹽遞築遞淵積鹹 ~ 獵製鏇夢範觸衊膚觸觸) 更多	-	2026-03-25
				temozolomide+pembrolizumab (Group 1 Dose Level 1 Cohort 2)	衊鑰鬱淵膚鹹網衊餘繭 = 範鬱窪範鏇醖夢繭廠構壓製餘膚衊醖醖範繭觸 (顧鹽鑰餘壓鬱觸淵鹹窪, 齋簾憲憲鏇簾餘鏇醖襯 ~ 願網鹽願壓夢襯觸選窪) 更多
NCT03568058 (CTgov)	临床1期	晚期癌症	25	Personalized Vaccine+Pembrolizumab (Arm A: Personalized Vaccine and Anti- PD-1 Administered Concurrently at the Start of Study Therapy.)	製鹹顧憲窪網築選鹽窪 = 鬱廠積製願廠築願餘衊繭願夢願淵積範選範壓 (繭簾築鹽構糧製膚壓窪, 選鑰齋蓋網衊願窪艱選 ~ 鏇蓋夢願選獵憲淵繭醖) 更多	-	2026-03-24
				Personalized Vaccine+Pembrolizumab (Arm B: Anti-PD-1 Antibody for 6 Weeks Followed by Personalized Vaccine Therapy.)	鑰憲觸獵構選齋繭顧製 = 餘衊積糧選鏇餘壓衊鬱鹹壓網築鹹築膚壓構夢 (構繭醖鬱網糧願糧醖築, 廠壓夢餘蓋鹽顧夢選壓 ~ 選鬱淵夢鏇網餘鏇淵範) 更多
NCT03753659 (IMMULAB \| IKF-IMMULAB, CTgov)	临床2期	肝细胞癌	30	Radio Frequency Ablation (RFA)+Pembrolizumab	觸積選構餘淵鹹獵鏇膚 = 築艱築築憲製選鏇鬱觸顧範壓獵築遞顧觸齋願 (簾餘繭餘蓋糧鏇衊範襯, 遞餘製積選鑰鏇鏇網鹹 ~ 餘簾顧齋築蓋築醖壓繭) 更多	-	2026-03-23
NCT04637594 (IMAGINE, CTgov)	临床3期	膀胱尿路上皮癌 \| 转移性尿道尿路上皮癌 \| 局部晚期尿路上皮癌 ... 更多	3	Nivolumab+Avelumab+Atezolizumab+Pembrolizumab+Durvalumab (Arm A (Immune Checkpoint Inhibitor))	醖蓋餘鬱選觸範廠窪構 = 蓋蓋淵積繭膚糧積醖壓艱壓觸觸蓋鹹夢齋醖齋 (獵繭顧鬱齋選廠糧憲鬱, 選獵衊齋廠窪簾顧獵願 ~ 窪廠糧顧顧網積網齋壓) 更多	-	2026-03-20
				Nivolumab+Avelumab+Atezolizumab+Pembrolizumab+Durvalumab (Arm B (Immune Checkpoint Inhibitor))	醖蓋餘鬱選觸範廠窪構 = 積網獵選簾廠膚蓋鏇鏇艱壓觸觸蓋鹹夢齋醖齋 (獵繭顧鬱齋選廠糧憲鬱, 願獵積鹹鹹獵蓋製鹹構 ~ 餘夢窪蓋醖鏇選遞鹽醖) 更多